As of June 09, 2026, Ovid Therapeutics's top three insider holders are Pharmaceutical Co Ltd Takeda (TenPercentOwner, 7.00Mn shares), Jeremy M Levin (Executive Chairman, 3.74Mn shares), Amit Rakhit (President And Cmo, 726.82K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Jeremy M Levin | Executive Chairman | 3,735,048 | 0 | 25 Mar, 2026 |
| Jeffrey A Rona | Cbfo | 156,313 | 0 | 02 Mar, 2026 |
| Bart Friedman | - | 8,789 | 0 | 09 Apr, 2026 |
| Pharmaceutical Co Ltd Takeda | - | 0 | 7,000,000 | 09 Dec, 2025 |
| Amit Rakhit | President And Cmo | 726,823 | 0 | 16 Jul, 2021 |
| Thomas Michael Perone | General Counsel, Secretary | 28,125 | 0 | 26 Feb, 2024 |
| Jason Tardio | Chief Operating Officer | 28,125 | 0 | 26 Feb, 2024 |
| Kevin Joseph Fitzgerald | - | 17,578 | 0 | 09 Apr, 2026 |
| Margaret A. Alexander | President And Ceo | 61,750 | 0 | 02 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 07 Apr, 2026 | Bart Friedman | Common Stock | A | 8,789 | $2.56 | 8,789 | D | A |
| 07 Apr, 2026 | Kevin Joseph Fitzgerald | Common Stock | A | 17,578 | $2.56 | 17,578 | D | A |
| 23 Mar, 2026 | Jeremy M Levin | Common Stock | A | 47,333 | $1.40 | 3,735,048 | D | M |
| 23 Mar, 2026 | Jeremy M Levin | Series A Warrant (right to buy) | D | 47,333 | $0.00 | 0 | D | M |
| 26 Feb, 2026 | Kevin Joseph Fitzgerald | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 26 Feb, 2026 | Barbara Gayle Duncan | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 26 Feb, 2026 | Bart Friedman | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 23 Feb, 2026 | Margaret A. Alexander | Common Stock | D | 11,656 | $1.45 | 61,750 | D | S |
| 26 Feb, 2026 | Jeremy M Levin | Employee Stock Option (Right to Buy) | A | 957,000 | $0.00 | 957,000 | D | A |
| 23 Feb, 2026 | Jeffrey A Rona | Common Stock | D | 8,541 | $1.45 | 88,188 | D | S |
| 26 Feb, 2026 | Karen Bernstein | Employee Stock Option (Right to Buy) | A | 65,000 | $0.00 | 65,000 | D | A |
| 26 Feb, 2026 | Margaret A. Alexander | Employee Stock Option (Right to Buy) | A | 1,435,000 | $0.00 | 1,435,000 | D | A |
| 26 Feb, 2026 | Jeffrey A Rona | Common Stock | A | 68,125 | $0.00 | 156,313 | D | A |
| 26 Feb, 2026 | Jeffrey A Rona | Employee Stock Option (Right to Buy) | A | 408,750 | $0.00 | 408,750 | D | A |
| 04 Jan, 2026 | Margaret A. Alexander | Employee Stock Option (right to buy) | A | 890,000 | $0.00 | 890,000 | D | A |
| 15 Dec, 2025 | Jeremy M Levin | Common Stock | A | 71,000 | - | 3,687,715 | D | C |
| 11 Dec, 2025 | Jeremy M Levin | Series B Convertible Preferred Stock | A | 71 | - | 71 | D | P |
| 11 Dec, 2025 | Jeremy M Levin | Series A Warrant (right to buy) | A | 47,333 | - | 47,333 | D | P |
| 11 Dec, 2025 | Jeremy M Levin | Series B Warrant (right to buy) | A | 35,500 | - | 35,500 | D | P |
| 15 Dec, 2025 | Jeremy M Levin | Series B Convertible Preferred Stock | D | 71 | $0.00 | 0 | D | C |